Form 4: Vaccinex CFO Jill Sanchez Reports Stock Option Grant

Jill Sanchez, CFO of Vaccinex, Inc., reports the acquisition of stock options.

Summary

• Jill Sanchez, the Chief Financial Officer of Vaccinex, Inc., filed a Form 4.
• The report details changes in her beneficial ownership of securities.
• The earliest transaction date reported is March 20, 2024.
• Sanchez acquired 805 stock options at a price of $0 on March 20, 2024, exercisable until March 20, 2034.
• These options vest one-fourth on each of the first four anniversaries of the March 30, 2024 grant date.
• Sanchez also holds other stock options with varying exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency regarding the compensation and equity ownership of key executives.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to incentivize the CFO to improve company performance.
• Employees may see the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Vaccinex, VCNX, Jill Sanchez, CFO, stock options, Form 4, beneficial ownership, securities, insider trading